To explore that disparity, Kay and her team analyzed gene expression data from more than 6,000 samples across public databases and conducted a meta-analysis focused on blood-based immune cells. Their study identified 61 genes that were differentially expressed by sex in adults with asthma. Many of these genes were associated with key immune pathways—including those involving eosinophils, lymphocytes, and type 2 inflammation.
To detect subtle biological differences, the team pooled asthma gene expression data from more than 3,500 individuals and validated key findings in a local Yale cohort, where sex-biased genes aligned with asthma traits such as lung function and symptom severity.
The researchers found that gene expression differences aren’t just present between males and females—they also change with age and tissue type. They also found that different patterns emerged in children than in adults, suggesting that biological sex and hormonal fluctuations may shape asthma risk and severity across the lifespan.
“We see asthma symptoms and severity change during puberty, pregnancy, and menopause, even within the menstrual cycle, suggesting that hormones are a strong contributor to sex differences,” Kay says. “These differences in pathology can affect inflammation and possibly gene expression too.”
The findings could have important implications for treatment, the researchers say. Many newer asthma therapies—like biologics—target specific parts of the immune system. Understanding sex-specific immune profiles could eventually help match the right drug to the right patient.
“Right now, we don’t typically consider sex when choosing asthma treatment plans,” Kay says. “But these insights can start the conversation and ideally bring us closer to personalized asthma care.”
Jose Gomez, MD, Yale PCCSM associate professor of medicine and senior author of the study, notes that the aim of P2MED is to integrate high‑definition biomarkers from transcriptomics and genetics with dedicated clinical phenotypes.